➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Mallinckrodt
Johnson and Johnson
AstraZeneca
Harvard Business School

Last Updated: September 29, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for pyrotinib

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for pyrotinib?

pyrotinib is an investigational drug.

There have been 63 clinical trials for pyrotinib. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2016.

The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, and Neoplasms. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Fudan University, and Chinese Academy of Medical Sciences.

There are three US patents protecting this investigational drug and fifty international patents.

Recent Clinical Trials for pyrotinib
TitleSponsorPhase
Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II TrialShengjing HospitalPhase 2
Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based ChemotherapyJiangsu HengRui Medicine Co., Ltd.Phase 3
Granisetron Transdermal Patch for Prophylaxis of Nausea and Vomiting in Patients Receiving Oral Anticancer AgentsFudan UniversityPhase 2

See all pyrotinib clinical trials

Clinical Trial Summary for pyrotinib

Top disease conditions for pyrotinib
Top clinical trial sponsors for pyrotinib

See all pyrotinib clinical trials

US Patents for pyrotinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
pyrotinib   Start Trial 6-amino quinazoline or 3-cyano quinoline derivatives, preparation methods and pharmaceutical uses thereof Jiangsu Hengrui Medicine Co., Ltd. (Lianyungang, Jiangsu, CN) Shanghai Hengrui Pharmaceutical Co., Ltd. (Shanghai, CN)   Start Trial
pyrotinib   Start Trial Crystalline form I of tyrosine kinase inhibitor dimaleate and preparation methods thereof Jiangsu Hengrui Medicine Co., Ltd. (Lianyungang, Jiangsu, CN)   Start Trial
pyrotinib   Start Trial Pharmaceutical uses of 6-amino quinazoline or 3-cyano quinoline derivatives Jiangsu Hengrui Medicine Co., Ltd. (Lianyungang, Jiangsu, CN) Shanghai Hengrui Pharmaceutical Co., Ltd. (Shanghai, CN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for pyrotinib

Drugname Country Document Number Estimated Expiration Related US Patent
pyrotinib Australia 2010292790 2029-09-14   Start Trial
pyrotinib Brazil 112012005760 2029-09-14   Start Trial
pyrotinib Canada 2774099 2029-09-14   Start Trial
pyrotinib China 102020639 2029-09-14   Start Trial
pyrotinib China 102471312 2029-09-14   Start Trial
pyrotinib Denmark 2479174 2029-09-14   Start Trial
pyrotinib European Patent Office 2479174 2029-09-14   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Mallinckrodt
Johnson and Johnson
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.